Therapeutic potential of neuregulin-1 in cardiovascular disease

Drug Discov Today. 2013 Sep;18(17-18):836-42. doi: 10.1016/j.drudis.2013.01.010. Epub 2013 Feb 4.

Abstract

Neuregulin-1 (NRG-1)/ErbB signaling has an indispensable role in cardiac development and in the maintenance of the structural and functional integrity of the human adult heart in health and disease. Several animal studies have now demonstrated the therapeutic effects of NRG-1 during acute cardiac injury and during chronic heart failure, with improvements in cardiac performance and animal survival. Phase I and II clinical trials for chronic heart failure in humans are now in progress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiovascular Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular System / drug effects*
  • Cardiovascular System / metabolism
  • Cardiovascular System / physiopathology
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism
  • Humans
  • Neuregulin-1 / metabolism
  • Neuregulin-1 / therapeutic use*
  • Receptor, ErbB-2 / drug effects
  • Receptor, ErbB-2 / metabolism
  • Receptor, ErbB-4
  • Recombinant Proteins / therapeutic use
  • Signal Transduction / drug effects

Substances

  • Cardiovascular Agents
  • Neuregulin-1
  • Recombinant Proteins
  • ERBB4 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2
  • Receptor, ErbB-4